Semaglutide for people with obesity and resistant hypertension (SUPPORT): a pilot, randomized, parallel-group, integrated, multicentre clinical trial.
Key facts
- Where
- Dublin, Dublin 8, Galway és Limerick, ÍrországSee the 5 sites
- Phase
- 3. fázis
Where in Írország
- Centric Health Navan RoadDublin, ÍrországNo longer taking part
- St James's HospitalDublin 8, ÍrországNo longer taking part
- TURLOUGHMORE MEDICAL CENTREGalway, ÍrországNo longer taking part
- University Hospital GalwayGalway, ÍrországNo longer taking part
- Griffin Daly Medical CentreLimerick, ÍrországNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Trinity College Dublin
- Trial code
- EU 2024-513958-29-00
- Record updated
- 2026. július 21.
- Original description
To assess the feasibility of conducting a trial to determine whether targeting obesity with semaglutide in patients with resistant hypertension improves blood pressure control versus placebo.Read full original descriptionShow less
To assess the feasibility of conducting a trial to determine whether targeting obesity with semaglutide in patients with resistant hypertension improves blood pressure control versus placebo.
Inclusion: Obesity defined as a BMI ≥ 30kg/m2; Resistant hypertension defined as: o Mean home systolic BP ≥ 130 mmHg measured in duplicate at a minimum of 6 timepoints. o Prescribed three or more anti-hypertensive medications, which should include a diuretic; Prescribed three or more anti-hypertensive medications at optimal doses, one of which should include a diuretic; Written informed consent to partake and availability for trial duration; Adults, aged ≥18 years at the time of signing informed consent.
Exclusion: Treatment with any GLP-1 RA or any medication for the indication of obesity within the past 90 days before screening; Previous surgery for weight reduction or major gastro-intestinal tract surgery; Presence or history of chronic pancreatitis or pancreatic cancer; Hypersensitivity to semaglutide, another GLP1-RA, or excipients of Ozempic®/Wegovy®; Personal/family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome; Comorbidities: Diabetes with a HbA1c ≥53mmol/L or a requirement for insulin treatment or diabetic retinopathy, previous pancreatitis/pancreatic cancer, end stage renal disease (eGFR <15ml/min), congestive heart failure NYHA class IV, limited life expectancy; Patients with severe renal impairment (eGFR < 30 ml/min1.73m2) including patients with end-stage renal disease, patients with severe hepatic impairment, congestive heart failure NYHA class IV, limited life expectancy; Diabetes with a HbA1c ≥53mmol/L or a requirement for insulin treatment or diabetic retinopathy; Otherwise considered unsuitable by the principal investigator or their primary doctor; An episode of acute pancreatitis within the last 180 days; Female who is pregnant, breastfeeding or intends to become pregnant or is of childbearing potential and not using a highly effective contraceptive method.